Multiple exostosis disease is one of the hereditary diseases with autosomal dominant transmission. It is characterized by the proliferation of bone protuberances, especially located in the metaphysis of long bones.
Introduction
Multiple exostosis disease, first described by French surgeon Alexis Boyer in 1814, is a rare genetic disease with autosomal dominant transmission 1 . There is a family history in about 60% of cases 2 . Exostosis is composed of bone tissue with a peripheral cortex, central spongy bone, and a cartilaginous cap 2 . All bones developing by endochondral ossification can be affected (long bones, vertebrae, medial portion of the clavicle and bone of the base of the skull) 3 . Bones that develop by membrane ossification are not affected (flat bones, lateral portion of the clavicle), except in special cases 3 . Exostosis develops during childhood. They stabilize with progressive regression of the cartilage cap after the end of growth 4 .
Epidemiology
Multiple exostosis disease is a rare condition with an estimated prevalence of 1/500,000 in the western population 5, 6 . It is less reported in North Africa 7, 8 . In sub-Saharan Africa, only 20 observations to our knowledge were described between 1999 and 2018 (table below) 9, 10, 11, 12, 12, 13, 14, 15 .
Physiopathology

Genetic
Multiple exostosis disease is associated with a mutation of the genes EXT1 (chromosome 8q23-q24) 16 and/or EXT2 (chromosome 11p11-p13) 17 , found in 80% to 90% of cases. An EXT3 gene (chromosome 19) has also been described, but its responsibility for the development of the disease remains to be determined 18 . EXT genes are tumor suppressors: the loss of heterozygosity related to their mutation would be an inductive event in the development of exostosis 19 . These genes code for transmembrane type II glycoproteins, exostosin 1 and 2 20, 21 , which have glycosyltransferase action 2, 21 . These two proteins, mainly located in the endoplasmic reticulum form a Golgilocalized heterooligomeric complex that catalyzes the polymerization of heparan sulfate (HS).
The consensus would be that exostosin 1 would have the most important synthesis activity and exostosin 2 would stabilize the heterodimer in the Golgi apparatus. The mutation of the EXT1 and EXT2 genes is therefore responsible for the decrease in the concentration of heparan sulfates. Moreover, the exostosis biopsy study of patients with multiple exostosis disease showed a higher concentration in heparanase cartilage compared to healthy controls and solitary exostosis 2 . This also suggests an increase in the degradation of heparan sulfates 22, 23 .
Consequence of heparan sulfate deficiency
During the chondrocyte maturation phase, chondrocytes go through the prehypertrophic, hypertrophic and then enter apoptosis 2 . They are organized in regular columns in the metaphysis allowing longitudinal growth of long bones 2, 24 .
Heparan sulfate chains have a co-receptor role in many metabolic pathways, such as Fibroblast Growth Factor (FGF), Tumor Growth Factor (TGF), Bone Morphogenetic Protein (BMP), Wnt, Indian Hedgehog (Ihhh), PTHrp 25 . The integrity of these signaling pathways is essential for the different phases of chondrocyte maturation at the growth plate during endochondral ossification 24 . The pathophysiological hypothesis is that the decrease in HS on the surface of chondrocytes would slow down their differentiation into hypertrophic chondrocytes, giving them a proliferation advantage at the same time. This proliferation would lead to a lack of ossification of the perichondrium, explaining the growth of ectopic cartilage 26 .
The distribution of Ihh in the growth plate is dependent on the concentration of heparan sulfate: the mutation of EXT1 induces an increase in the diffusion zone of Ihh with extension towards the perichondrium. Moreover, Ihh causes an increase in chondrocyte proliferation and a decrease in differentiation into hypertrophic chondrocytes 27 . This may be related to the fact that heparan sulfate can bind to Hedgehog ligands and modulate their diffusion in the extracellular medium: the decrease of heparan sulfate concentration would lead to a decrease in the possibility of ligand binding and activation of the Hedgehog signal in patients with multiple exostosis disease 28 .
Heparan sulfates would limit the diffusion zone of Wnt (a major actor in bone and cartilage formation) by facilitating the binding of Wnt to its receptor 28 . Thus, the action of the Wnt signal is reduced compared to healthy individuals, which could partly explain the abnormalities in the organization of the growth plate in affected patients 28, 29 .
For the FGF signal, the decrease in heparan sulfate concentration results in a marked decrease in the activation of the MAP kinase pathway, which are intracellular mediators essential to the metabolic pathway of FGF 29 .
The analysis of BMP receptors and BMP expression in the cartilage layer of exostoses is similar to the rates found in the growth plate. This could explain the presence of a prolonged proliferation of exostosis in affected patients 30 .
The presence of heparanase has been identified in exostosis chondrocytes of patients with multiple exostosis disease 2 .
Finally, the position in the growth plate of mutated chondrocytes could be important in the development of exostosis. In a zebrafish model, the implantation of mutated chondrocytes dak-/-(equivalent to EXT) in the center of the growth plate is without consequence: the mutated cells are placed in the regular columns, "reoriented" by the adjacent normal cells. Inversely, by implanting these same mutated cells on the periphery of the growth plate, dak-/-chondrocytes grow perpendicular to the growth plate 31 . This observation highlights the role of the cartilage-perichondrium transition zone in the development of bone exostosis and may partly explain the absence of development of intracartilage lesions, such as enchondromes in presence of EXT mutations 
Diagnosis
Positive diagnosis
The diagnosis of multiple exostosis disease is often early. It is performed in the majority of cases before the age of 5 years, because of the accessible nature of the bone masses, which are however painless 5, 8 . locations are mainly active metaphyses of bones developing by endochondral ossification: mainly in the distal femur, fibula and proximal tibia, proximal humerus ( Figure 1 ). Some locations are rare but potentially serious, such as ribs, rachis or pelvis, due to proximity to important structures such as the spinal cord, lungs, heart or urogenital organs 14, 33 ( Figure 2 ).
Patients are often small, with short limbs, deformed in two-thirds of patients 1 . The most common orthopedic complications include bone synostosis, limb inequality, a b c . The typical deformity mainly affecting ulna is called Bessel Hagen disease 2, 33 ( Figure 3 ).
The diagnosis of exostosis is essentially radiological 34 
.
In the typical form, histology is not required 34 . The radiological forms of exostosis are multiple but can be individualized into 3 types: pedicle forms (narrow implantation and always inclined towards the diaphysis), sessile forms, characterized by a wide implantation on the metaphysis and diaphysis and cauliflower forms 34 .
The tomodensitometry shows continuity between the spongy metaphyseal bone spans and the center of the exostosis (Figure 4 ). This element is pathognomonic, however, it is often missing on standard radiographs 34 
Magnetic resonance imaging is the best radiological technique to assess the relationship of exostosis with neighboring anatomical structures and to evaluate the cartilage cap. The mineralized parts are hyposignal in all sequences, while the non-mineralized parts with a high water content are hyposignal T1 and hypersignal intense T2. These characteristics allow the precise measurement of the thickness of the cartilage cap by determining its limit with the overlying muscles 34 .
Differential diagnosis
Multiple exostosis disease can be confusing due to certain diseases, in particular: -Metachondromatosis, which is an autosomal dominant disease induced by the mutation of the PTPN11 gene. It is characterized by exostoses that move towards the joint 35 .
The disease progresses to spontaneous regression 35 .
-Langer-Giedon syndrome, which is linked to a mutation of the EXT1 and TRPS1 genes. Clinical presentation combines multiple exostoses, mental retardation, abnormalities of the skull and face and digital -Potocki-Shaffer syndrome, which is linked to a mutation of the EXT2 and ALX4 genes. Clinical presentation combines multiple exostoses, skull ossification deficiency (enlarged parietal foramen), skull-facial dysostosis and mental retardation 36 .
-Progressive ossifying fibrodysplasia, which is linked to a mutation in the ACVR1 gene (activin receptor) inducing activation of the ALK2 receptor at BMP1. This disease combines an overall ossification deficiency, a short femoral neck, an enlargement of the metaphyses and the presence of exostosis, especially of the proximal tibia 37 .
Prognosis
Depending on its location and volume, exostosis can be responsible for complications that can be severe: osteoarticular complications (osteo-articular deformities, bone fractures, osteomyelitis), compressions of adjacent structures (nerve compressions, vascular compressions, intra-thoracic compressions) 38, 39, 40, 41, 42, 43, 44 .
The most serious complication is malignant transformation, which can occur in 2 to 5% of cases 37 . It is a chondrosarcoma in 90% of cases 37 . The predictive signs of malignant degeneration are the increase in size of exostoses, especially after the end of growth, the presence of local inflammatory signs, an increase in the cartilaginous cap thickness (greater than 2 cm in adults or 3 cm in children) (figure 5) 45 . Locations with pelvic and scapular belts are more susceptible to degeneration 46 .
Processing and monitoring
The treatment proposed for multiple exostosis disease is mainly surgical. Surgery should be offered in case of symptoms (pain, increases in exostosis volumes after growth has ceased, compressions of neighboring organs) 34, 47 .
In case of osteochondromas stability, regular close monitoring is necessary due to the risk of malignant degeneration 34 . Computed tomography and magnetic resonance tomography (MRI) are an important part of this monitoring 34 .
Conclusion
Multiple exostosis disease is a rare disease, more reported in Western literature. It results in exostosis in the metaphyses of long bones and more rarely in the axial skeleton. The most feared complication is the malignant transformation into chondrosarcoma, which requires close monitoring of these patients. Despite the progress of knowledge about the disease, current treatments remain purely symptomatic. However, there are many research pathways, and the target of growth plate actors (Ihh, BMP, FGF) and heparan sulfate metabolism could generate therapeutic leads.
